» Articles » PMID: 29736203

MiR-520d-3p Antitumor Activity in Human Breast Cancer Via Post-transcriptional Regulation of Spindle and Kinetochore Associated 2 Expression

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2018 May 9
PMID 29736203
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) play an important role in human tumorigenesis as oncogenes or tumor suppressors by directly binding to the 3'-untranslated region of their target mRNAs. MiR-520d-3p has been reported as a tumor suppressor gene in ovarian cancer and gastric cancer, while the function of miR-520d-3p in human breast cancers is still uninvolved. In this study, we initially identified that the expression of miR-520d-3p was significantly reduced in breast cancer specimens and cell lines. The restoration of miR-520d-3p expression not only reduced breast cancer cell viability by causing the accumulation of G2 phase and cell apoptosis, but also inhibited tumorigenicity . In addition, as a critical target of miR-520d-3p, the activity of spindle and kinetochore associated 2 (SKA2) was greatly inhibited by miR-520d-3p, and overexpression of miR-520d-3p decreased the expression of SKA2. SKA2 downregulation suppressed cell viability, whereas restoration of SKA2 expression significantly reversed the inhibitory effects of miR-520d-3p antitumor activity. Furthermore, SKA2 was frequently overexpressed in clinical specimens and cell lines, and the expression levels were statistically inversely correlated with miR-520d-3p expression. In conclusion, our data demonstrated that miR-520d-3p antitumor activity is achieved by targeting the SKA2 in human breast cancer cells, suggesting that miR-520d-3p may be a potential target molecule for the therapy.

Citing Articles

MiR-520d-3p suppresses the proliferation and epithelial-mesenchymal transition of cervical cancer cells by targeting ZFP36L2.

Zhang Y, Tian F, Zhao J Heliyon. 2023; 9(8):e18789.

PMID: 37600385 PMC: 10432607. DOI: 10.1016/j.heliyon.2023.e18789.


The Role of Dexmedetomidine in Tumor-Progressive Factors in the Perioperative Period and Cancer Recurrence: A Narrative Review.

Cai Q, Liu G, Huang L, Guan Y, Wei H, Dou Z Drug Des Devel Ther. 2022; 16:2161-2175.

PMID: 35821701 PMC: 9271281. DOI: 10.2147/DDDT.S358042.


HOXA cluster antisense RNA 2 elevates KIAA1522 expression through microRNA-520d-3p and insulin like growth factor 2 mRNA binding protein 3 to promote the growth of vascular smooth muscle cells in thoracic aortic aneurysm.

Ou M, Chu Y, Zhang Q, Zhao H, Song Q ESC Heart Fail. 2022; 9(5):2955-2966.

PMID: 35730141 PMC: 9715842. DOI: 10.1002/ehf2.13968.


Overexpression of SKA3 correlates with poor prognosis in female early breast cancer.

Zhong Y, Zhuang Z, Mo P, Lin M, Gong J, Huang J PeerJ. 2022; 9:e12506.

PMID: 34993016 PMC: 8675262. DOI: 10.7717/peerj.12506.


MicroRNA-520d-3p suppresses melanoma cells proliferation by inhibiting the anti-silencing function 1B histone chaperone.

Shi X, Xu X, Shi N, Chen Y, Fu M Bioengineered. 2021; 12(2):10703-10715.

PMID: 34872448 PMC: 8809954. DOI: 10.1080/21655979.2021.2001914.


References
1.
Zhang M, Gao C, Yang Y, Li G, Dong J, Ai Y . MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1. Cell Physiol Biochem. 2017; 42(1):211-221. DOI: 10.1159/000477314. View

2.
Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W . miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3'UTR of CD46. Cancer Biol Ther. 2010; 10(3):232-41. DOI: 10.4161/cbt.10.3.12277. View

3.
Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H . miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 2008; 68(13):5004-8. DOI: 10.1158/0008-5472.CAN-08-0180. View

4.
Lan H, Lu H, Wang X, Jin H . MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015; 2015:125094. PMC: 4385606. DOI: 10.1155/2015/125094. View

5.
Nishimura M, Jung E, Shah M, Lu C, Spizzo R, Shimizu M . Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013; 3(11):1302-15. PMC: 3855315. DOI: 10.1158/2159-8290.CD-13-0159. View